Incyte Corporation is a Wilmington, Delaware-based drug discovery and development company focused on developing proprietary small molecule drugs for oncology, inflammation, and diabetes. Since the beginning of 2009, we have focused our efforts on clinical programs that we believe have the greatest likelihood of creating near-term value and on compounds that we believe a company of our size can effectively develop and commercialize on its own, or that we can further develop and commercialize through strategic relationships. Currently, our highest priority program involves our JAK inhibitors. Our JAK inhibitor program includes an oral formulation of INCB018424 as a treatment for myeloproliferative disorders (myelofibrosis, polycythemia vera, and essential thrombocythemia) and certain other oncology indications, a topical formulation of INCB018424 for psoriasis, and an oral formulation of INCB28050 for rheumatoid arthritis and other chronic inflammatory conditions.
For additional information on Incyte, visit the Company's Web site at www.incyte.com.